HCA Guides FY EPS to $28.70-$30.50
HCA sits 30% above its 52-week low of $353.99.
Summary
HCA put a full-year EPS range of $28.70 to $30.50 on the table, and now sees the year landing in the upper half of its guidance. That is the number that matters for a hospital operator trading near $461 a share, since it frames how much of the recent cost pressure is already baked into the year. The company also guided full-year revenue to $77B to $79.5B, net income to $6.3B to $6.7B and 2026 adjusted EBITDA to $15.4B to $16.1B. The backdrop is rough: Q2 revenue rose 8.7% to $20.23B, but uncompensated care jumped 29% and operating cash flow fell 44%, which is what drove the prior guidance cut. In the third quarter, revenue was $19.85B, EPS was $7.27, adjusted EPS was $7.22 and adjusted EBITDA was $3.92B, with profit slipping even as revenue rose. This range is the company's own reset of expectations against that deterioration.
At the time of this announcement, HCA was trading at $460.95 on NYSE in the Life Sciences sector, with a market capitalization of approximately $100.7B. The 52-week trading range was $353.99 to $556.52. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.